Mechanochemical ablation in patients with chronic venous disease: A prospective multicenter report

Bishawi, Muath; Bernstein, Rick; Boter, M; Draughn, D; GOULD, C. W.; Hamilton, Craig S.; Koziarski, J.

doi:10.1177/0268355513495830

Cited by 50 publications

(38 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bishawi et al indicate that this procedure has a very high effectiveness, reaching 97% in the first 6 weeks after the procedure. Effectiveness is maintained at the level of 96% over 2 years of follow-up [13]. Elias estimated the effectiveness at 96.7% in a follow-up lasting 260 days [14].…”

Section: Discussionmentioning

confidence: 96%

Application of endovenous mechanochemical ablation (MOCA) with Flebogrif™ to treat varicose veins of the lower extremities: a single center experience over 3 months of observation

Zubilewicz

Terlecki

et al. 2017

Acta Angiologica

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Application of endovenous mechanochemical ablation (MOCA) with Flebogrif™ to treat varicose veins of the lower extremities: a single center experience over 3 months of observation

Zubilewicz

Terlecki

et al. 2017

Acta Angiologica

View full text Add to dashboard Cite

show abstract

“…showed anatomical success rates of 88% after RFA [10]. Our recent study on MOCA™ in SSV showed an occlusion rate of 97% in the group treated according to our current study protocol [17]. A Chi-square test with a one-sided 0.05 significance has a power of 80% to observe no difference between both groups, when each group consists of 74 patients (non-inferiority principle, range 2%).…”

Section: Method/designmentioning

confidence: 88%

“…Patients were satisfied after treatment [14]. Several other studies reported promising data on feasibility, safety, anatomical and clinical success regarding MOCA treatment in GSV insufficiency, without major complications [15–17]. …”

Section: Introductionmentioning

confidence: 99%

Mechanochemical endovenous ablation versus radiofrequency ablation in the treatment of primary small saphenous vein insufficiency (MESSI trial): study protocol for a randomized controlled trial

Boersma

Eekeren

Kelder

et al. 2014

Trials

View full text Add to dashboard Cite

BackgroundMinimally invasive endothermal techniques, for example, radiofrequency ablation (RFA), have revolutionized the treatment of insufficient truncal veins and are associated with an excellent outcome. The use of thermal energy requires the instillation of tumescent anesthesia around the vein. Mechanochemical endovenous ablation (MOCA™) combines mechanical endothelial damage, using a rotating wire, with simultaneous infusion of a liquid sclerosans. Tumescent anesthesia is not required as no heat is used. Prospective studies using MOCA™ in both great and small saphenous veins showed good anatomical and clinical results with fast postoperative recovery.Methods/DesignThe MESSI trial (Mechanochemical Endovenous ablation versus radiofrequency ablation in the treatment of primary Small Saphenous vein Insufficiency) is a multicenter randomized controlled trial in which a total of 160 patients will be randomized (1:1) to MOCA™ or RFA. Consecutive patients with primary small saphenous vein incompetence, who meet the eligibility criteria, will be invited to participate in this trial. The primary endpoint is anatomic success, defined as occlusion of the treated veins objectified with duplex ultrasonography at 1 year follow-up. Secondary endpoints are post-procedural pain, initial technical success, clinical success, complications and the duration of the procedure. Initial technical success is defined as the ability to position the device adequately, treat the veins as planned and occlude the treated vein directly after the procedure has been proven by duplex ultrasonography. Clinical success is defined as an objective improvement of clinical outcome after treatment, measured with the Venous Clinical Severity Score (VCSS). Power analyses are conducted for anatomical success and post-procedural pain.Both groups will be evaluated on an intention-to-treat principle.DiscussionThe hypothesis of the MESSI trial is that the anatomic success rate of MOCA™ is not inferior to RFA. The second hypothesis is that post-procedural pain is significantly less after MOCA compared to RFA.Trial registrationTrial registration: NTR4613 Date of trial registration: 28 May 2014.

show abstract

“…One-month to six-month occlusion rates of >90% were documented in other series. [15,16] When compared to RFA, it was reported that MOCA caused lesser postoperative pain and discomfort. [17] To document the non-inferiority of MOCA compared to RFA, Mechanochemical Endovenous Ablation versus RADiOfrequeNcy Ablation (MARADONA) Trial for GSV and Mechanochemical Endovenous Ablation versus Radiofrequency Ablation (MESSI) Trial for lesser saphenous vein (LSV) are still ongoing.…”

Section: Mechanochemical Ablationmentioning

confidence: 99%

What is popular may no longer be popular: Cyanoacrylate and other alternatives in surgical treatment of chronic venous insufficiency

Durukan¹

2017

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

Mechanochemical ablation in patients with chronic venous disease: A prospective multicenter report

Abstract: MOCA of the saphenous veins has the advantage of endovenous ablation without tumescent anesthesia, making it an almost pain-free procedure. High occlusion rates with significant clinical improvement can be achieved with this method at short term.

Cited by 50 publications

References 10 publications

Application of endovenous mechanochemical ablation (MOCA) with Flebogrif™ to treat varicose veins of the lower extremities: a single center experience over 3 months of observation

Application of endovenous mechanochemical ablation (MOCA) with Flebogrif™ to treat varicose veins of the lower extremities: a single center experience over 3 months of observation

Mechanochemical endovenous ablation versus radiofrequency ablation in the treatment of primary small saphenous vein insufficiency (MESSI trial): study protocol for a randomized controlled trial

What is popular may no longer be popular: Cyanoacrylate and other alternatives in surgical treatment of chronic venous insufficiency

Contact Info

Product

Resources

About